|
Contact: Megan Fellman at (847) 491-3115 or at |
Protein in Lou Gehrig’s Disease Linked to Neuron Death
EVANSTON, Ill.—French neurologist Jean-Martin Charcot first described amyotrophic lateral sclerosis (ALS) in 1869, but nearly 140 years later little is known about the cause of the devastating neurodegenerative disease, and there is no cure.
What is known about Lou Gehrig’s disease, as it is commonly called, is that misfolded and damaged proteins clump together in cells to form aggregates, and motor neurons die. But scientists have long debated whether or not the protein aggregates actually kill the cells.
Now a research team at Northwestern University, using mammalian neurons and live-cell time-lapse spectroscopy, has become the first to clearly link the presence of the ALS-associated mutant SOD1 protein aggregates with neuronal cell death. This evidence could help explain the disease process and eventually lead to new therapeutics.
In the study, published in the November issue of the Journal of Cell Biology, the scientists looked one at a time at neuronal cells expressing the mutant SOD1 protein and found that in cells where the protein accumulated and aggregates formed, 90 percent of the cells went on to die. (They died between 6 and 24 hours after aggregates were visually detected.) Cells that did not form aggregates did not die.
The study also provides a new understanding of the structure and composition of the deadly aggregates—one of the first studies to do so.
“We found that these aggregates are quite peculiar and very different from the aggregates formed in Huntington’s disease,” said Richard I. Morimoto, PhD, Bill A. and Gayle Cook Professor in Biological Sciences, who led the study. Dr. Morimoto is an expert in Huntington’s disease and on the cellular response to damaged proteins.
“In Huntington’s, the aggregate is very dense and impenetrable and binds irreversibly with other molecules in the cell,” he said. “In ALS, the aggregates are amorphous, like a sponge. Other proteins can go through the structure and interact with it, which may help explain why mutant SOD1 is so toxic.” Dr. Morimoto believes this surprising finding indicates that the structure of aggregates associated with other neurodegenerative diseases such as Parkinson’s and Alzheimer’s will be found to be different as well.
Looking at individual cells in a population, the researchers also found that cells side by side did different things. In cells expressing the same amount of damaged protein, some cells formed aggregates and died and others did not form aggregates and lived. Only a certain subset of at-risk cells went on to lose function and die.
“It would be terrifying if 100 percent of the cells expressing mutant proteins died,” said Dr. Morimoto. “This means that in many cases the cell’s protective machinery suppresses the damaged proteins, keeping the cell healthy. This discovery will be important to scientists looking to develop genetic suppressors and therapeutics.”
Dr. Morimoto’s team focused on SOD1 because it is a form of familial (hereditary) ALS in which a mutation in just one gene and its associated protein has devastating consequences to the cell. (Approximately 10 percent of ALS cases are familial.) This provides experimentalists with a powerful framework. For the other 90 percent the disease is not the result of one mutation but rather a series of many genetic events that debilitate motor neurons. With non-familial forms it is extremely difficult to design hypothesis-based experiments, said Dr. Morimoto.
The next question the researchers plan to address is what events lead to cell death once mutant SOD1 protein aggregates form in the cell. This knowledge would help scientists identify small molecules that could halt, arrest, or reverse the disease process.
In addition to Dr. Morimoto, other authors on the paper are Carina I. Holmberg, Soojin Kim, Gen Matsumoto (lead author), and Aleksandar Stojanovic, all formerly from Northwestern University.
The research was supported by the National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute on Aging, ALS Association, Huntington’s Disease Society of America, and the Daniel F. and Ada L. Rice Foundation.
